

Recombinant Varicella Zoster Virus ORF9 (aa 6-28; 76-100)

Catalog No.	CSI15904A	Quantity:	100 µg
	CSI15904B		0.5 mg
	CSI15904C		1.0 mg

Description: VZV is closely related to the herpes simplex viruses(HSV), sharing much genome homology. The known envelope glycoproteins (gB, gC, gE, gH, gI, gK, gL) correspond with those in HSV, however there is no equivalent of HSV gD. VZV virions are spherical and 150-200 nm in diameter. Their lipid envelope encloses the nucleocapsid of 162 capsomeres arranged in a hexagonal form. Its DNA is a single, linear, double-stranded molecule, 125,000 nt long. The virus is very susceptible to disinfectants, notably sodium hypochlorite. Within the body it can be treated by a number of drugs and therapeutic agents including aciclovir, zoster-immune globulin (ZIG), and vidarabine. The *E.Coli* derived recombinant protein contains the VZV ORF9 immunodominant regions, amino acids 6-28, 76-100.

Source: *E. coli*

Formulation: 25 mM Tris-Hcl, pH 8.0 + 1 mM EDTA and 50% glycerol.

Purity: Varicella protein is >95% pure as determined by 10% PAGE (coomassie staining).

Purification Method: Varicella was purified by proprietary chromatographic technique.

Specific Activity: Immunoreactive with sera of VZV-infected individuals.

Applications: Varicella Zoster antigen is suitable for ELISA and Western blots, excellent antigen for detection of VZV with minimal specificity problems.

Storage & Stability: Varicella protein although stable at 4°C for 1 week, should be stored below -18°C. **Please prevent freeze thaw cycles.**

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

